Nestlé Health Science Collaborate with Aimmune on Food Allergy Project

636141924688079833allergens.jpg

08 Nov 2016 --- Nestlé Health Science has announced that it will make an equity investment of $145 million in US-based Aimmune Therapeutics, to accelerate the development of technology designed to desensitize people with food allergies, protecting them from the consequences of accidental exposure. 

Up to 250 million people globally are estimated to suffer from food allergies, between 5-8% of who children and 1-2% of adults.

Amongst the top eight food allergies, peanut allergy, which is generally a lifelong condition, is estimated to impact 6 million people in the US and in Europe or between 0.6 and 1.3% of the population in the US.

Aimmune’s Characterized Oral Desensitization ImmunoTherapy approach to treating life-threatening food allergies is based on extensive independent scientific research.

It demonstrates that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular, food, through the oral administration of gradually increasing amounts of the allergens.

It aims to provide a transformative treatment option that goes beyond the current standard of care of avoiding food allergens and carrying epinephrine for administration in case of accidental exposure.

Greg Behar, CEO of Nestlé Health Science, who will take a seat on the Aimmune Board, stated: “Food allergies have a huge personal impact and are a health economic burden.”

“We are investing and innovating to change the approach to food allergy management with integrated approaches from diagnostics to nutrition solutions and now biologics, where Aimmune’s proprietary approach has transformational potential in lives of patients and families.”

Aimmune’s lead Characterized Oral Desensitization ImmunoTherapy product candidate, AR101 for peanut allergy, is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts designed to desensitize patients with peanut allergy.

The ongoing Phase III trial, conducted by Aimmune, is expected to deliver results in 4Q2017, which – if positive – may support the filing of marketing authorization in the US and Europe.

Stephen Dilly, CEO of Aimmune, said, “Nestlé Health Science is an ideal partner that brings a shared vision, global scale and complementary capabilities to this collaboration, making the whole more than the sum of the parts.”

“We are excited to have Nestlé Health Science alongside as we pursue our development plans and seek to realize the full promise of our CODIT approach by addressing the important questions in food allergy around optimizing treatments, achieving sustained unresponsiveness, and exploring the science around tolerance.”

Having already established a portfolio of nutritional solutions for pediatric food allergy and intolerances, the investment extends Nestlé Health Science’s interests in the food allergy arena.  

The strategic investment launches a two-year strategic collaboration between the two companies, the terms of which enable the parties to engage on Aimmune’s current and future oral immunotherapy development programs through a newly established pipeline forum.

Nestlé Health Science will provide ongoing scientific, regulatory and commercial expertise and advice to Aimmune through the pipeline forum, and in addition, has a three-month exclusive right of first negotiation for any development program in the event Aimmune considers licensing or partnering such a program.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

“Why overcomplicate nutrition?” Huel co-founder and CEO on market potential of complete meal replacements

22 Jun 2018 --- “People overcomplicate nutrition; it’s not rocket science. For the lay consumer, getting your nutrition right needn’t be that hard.” This is according to nutritionist James Collier, co-founder of Huel, a meal replacement brand currently seeing huge growth in Europe and the US. Launched three years ago, the company is reportedly one the fastest growing companies in the UK, with revenues of over £14 million (US$18.6 million) in 2017. 

Nutrition & Health News

Weekly Digest: Probiotics reduce bone loss in older women, Optibiotix expands reach in Italy

22 Jun 2018 --- This week in nutrition, Australian Whole Grain Week launched a new diet database in the hope to enhance healthy diets across the country. In research news, UK scientists warn that the normalization of plus-size body shapes may undermine obesity reduction efforts, while probiotics were found to have a significant protective effect for the bones of older women, and further research found that four cups of coffee seemed to protect the heart. Optimum Nutrition and Faber embarked on a campaign to improve American travel snacking habits and Optibiotix and Alfasigma partnered to commercialize Optibiotix's probiotic supplement in Italy. Lastly, this year’s Institute of Food Technologist (IFT18) in Chicago, US, will see NZMP launching a new milk protein ingredient and Lycored delivering some excitement on the floor with “culinary art.”

Nutrition & Health News

Plasma Nutrition technology found to significantly boost bioavailability of whey protein

21 Jun 2018 --- A University of South Florida study has found that Plasma Nutrition’s Ingredient Optimized technology can make whey protein more bioavailable than high DH hydrolyzed whey protein. The research was conducted on a double-blinded randomized cohort in a crossover design and compared the effects of 25g of non-hydrolyzed ioProtein whey protein isolate (WPI) to 25g of a high-DH hydrolyzed whey protein. The results show that ioWhey Protein is more bioavailable than hydrolyzed whey protein, demonstrating a 58 percent increase in leucine absorption and 60 percent increase in BCAA absorption.

Nutrition & Health News

More than a flavor: Flavoring substances stimulate immune defenses, study finds

21 Jun 2018 --- Not only do citric acid and spicy 6-gingerol from ginger add special flavors to food and beverages; both substances also stimulate the molecular defenses in human saliva, researchers from the Technical University of Munich (TUM) and the Leibniz-Institute for Food Systems Biology have found. The findings demonstrate the potential of flavor substances to have properties that go beyond the sensory.

Business News

Probiotic expansion: General Mills leads investment in GoodBelly parent

21 Jun 2018 --- General Mills' venture arm, 301 Inc., is leading a US$12 million round in funding in NextFoods the parent company of GoodBelly Probiotics. Additional capital is coming from existing investors, including Emil Capital Partners. NextFoods was founded in 2007 by Todd Beckman and Steve Demos, who founded WhiteWave Foods, the owner of Silk plant-based milk.

More Articles
URL : http://www.nutritioninsight.com:80/news/nestl%C3%A9-health-science-collaborate-with-aimmune-on-food-allergy-project.html